Hybridoma clones and monoclonal antibodies to ING4

1. A monoclonal antibody that is capable of specifically binding to human ING4, wherein the antibody is selected from the group consisting of:

(a) a monoclonal antibody produced by the hybridoma cell line BTIM-2, deposited with the ATCC as Patent Deposit No. PTA 120605;

(b) a monoclonal antibody produced by the hybridoma cell line BTIM-3, deposited with the ATCC as Patent Deposit No. PTA 120606; and

(c) a monoclonal antibody produced by the hybridoma cell line BTIM-4, deposited with the ATCC as Patent Deposit No. PTA 120607.

2. The monoclonal antibody of claim 1 , wherein the antibody is an IgG1, kappa chain isotype.

3. A monoclonal antibody produced by hybridoma cell line BTIM-4, ATCC accession number PTA 120607.

4. A method comprising the steps of:

(a) reacting an anti-ING4 monoclonal antibody with a sample collected from a subject, wherein the sample is at least one sample selected from the group consisting of a tissue sample, a blood sample, a serum sample, a plasma sample, and bodily fluid, wherein the anti-ING4 monoclonal antibody has the same epitope specificity as a monoclonal antibody produced by hybridoma cell line BTIM-4, ATCC accession number PTA 120607;

(b) detecting a level of ING4 protein in the sample.

5. The method according to claim 4 , wherein the anti-ING4 antibody is labeled.

6. The method according to claim 5 , wherein the anti-ING4 antibody is labeled with one or more labels selected from the group consisting of a biotin label, a fluorescent label, an enzyme label, a coenzyme label, a chemiluminescent label, and a radioactive isotope label.

7. The method of claim 4 , further comprising the steps of:

(d) reacting an anti-p-p65/ReIA antibody with the sample;

(e) detecting a level of p-p65/ReIA protein in the sample.